Luc Verelst, founder and chairman of Droia Ventures (not the Managing Partner listed in the query). See sector focus and contact routes.
Luc Verelst, founder and chairman of Droia Ventures (not the Managing Partner listed in the query), invests exclusively in early-stage biotech companies focused on oncology and genetic diseases like cystic fibrosis and hemophilia. The firm manages over €450 million and typically targets seed to early venture rounds, supporting innovative therapeutics with financial backing and scientific expertise. Notable portfolio companies include Actio Biosciences, Vicinitas Therapeutics, Unnatural Products (Series B, $45M), and Protego Biopharma (Series B, $130M). Verelst’s distinctive thesis centers on addressing unmet medical needs in difficult-to-treat conditions by accelerating novel drug development for severe patient outcomes.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Luxembourg.
Investors like Luc Verelst · Full investor directory · Investor access · Company funding database